Interaction of high dose rifampicin with dolutegravir

In their initial publication, Kengo et al. characterized the pharmacokinetics of high-dose rifampicin among patients with TB and HIV. They highlighted lower-than-expected exposures of rifampicin in their study participants, attributing this to lower bioavailability of the supplemental rifampicin‑only formulation used to alongside the standard dose fixed-dose combination formulation. Further details on this can be found in the publication here.

In the subsequent publication, Kengo et al. investigated the drug‑drug interaction between dolutegravir and rifampicin at standard and higher doses. They found that increasing the rifampicin dose from the standard 10mg/kg to 35 mg/kg resulted in a decrease of dolutegravir bioavailability. Further details can be read in the publication here.